effect overlay
activetrials
Multiple sclerosis
Multiple Sclerosis
CLOU

A randomized, open-label, parallel-group, non-inferiority study comparing efficacy, safety, and tolerability of remibrutinib after switching from ocrelizumab in participants living with relapsing multiple sclerosis, followed by open-label treatment with remibrutinib

HREC: 2025.026
Principal Investigator: Dr Ai-Lan Nguyen
Coordinator contact:
Funding: Commercial
Multiple sclerosis
Multiple Sclerosis
PRIMeS

Early detection and prevention of progressive disability in multiple sclerosis

HREC: 2023.123
Principal Investigator: Prof Tomas Kalincik
Coordinator contact:
Funding: Non-Commercial
Multiple sclerosis
Multiple Sclerosis
Outpatient Model of Care in Neuroimmunology

Human Centred Designed Model of Care in Neuroimmunology

HREC: 2023.035
Principal Investigator: Prof Tomas Kalincik
Coordinator contact: Katherine Fazzolari
Funding: Commercial
Multiple sclerosis
Multiple Sclerosis
Changes in Cerebrospinal Fluid (CSF) in MS

Changes in Cerebrospinal Fluid (CSF) in MS

HREC: 2020.017
Principal Investigator: Dr Mastura Monif
Coordinator contact:
Funding: Non-Commercial
Multiple sclerosis
Multiple Sclerosis
Early detection of neurodegeneration in MS

Early detection of neurodegeneration in MS

HREC: 2019.132
Principal Investigator: Prof Trevor Kilpatrick
Coordinator contact: Prof Tomas Kalincik
Funding: Non-Commercial